临床试验/NCT05660980

NCT05660980招募中1 期

Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

National Institute of Allergy and Infectious Diseases (NIAID)24 个研究点分布在 5 个国家目标入组 90 人开始时间: 2024年1月24日最近更新: 2026年5月19日

适应症

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方: National Institute of Allergy and Infectious Diseases (NIAID)
入组人数: 90
试验地点: 24
主要终点: AUC (Cohort 1, tablets)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of the study is to evaluate the pharmacokinetics (PK), safety, tolerability, and acceptability of a long-acting injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age

详细描述

This is a Phase I/II, multicenter, open-label, non-comparative study to evaluate the safety, tolerability, acceptability, and PK of oral CAB and oral RPV followed by long-acting injectable CAB (CAB LA) and long-acting injectable RPV (RPV LA) to propose the weight-band dosing in virologically suppressed children living with HIV-1 aged two to less than 12 years. The study will also assess the long-acting injectable regimen with and without an oral lead-in period in the same study population.

Following completion of the study, if it is not possible for participants to access injections of CAB LA and RPV LA from non-study sources all participants may enter a Study Safety Extension (SSE) period. During the SSE period ongoing safety information to monitor for toxicities will be collected.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Treatment
盲法: None

入排标准

年龄范围: 2 Years 至 11 Years（Child）
性别: All
接受健康志愿者: 否

入选标准

•, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b
•Parent or legal guardian is willing and able to provide written permission for child's study participation and, when applicable per institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written assent for study participation.
•Note: All sites must follow all applicable IRB/EC policies and procedures; for US sites, this includes single IRB (sIRB) policies and procedures.
•Age two years old to less than 12 years old at entry
•Body weight ≥10 kg and <40 kg at entry
•At entry, willing and able to comply with the study visit schedule and other study requirements, as determined by the site investigator or designee.
•Confirmed HIV-1-infection based on documented testing of two samples collected from two separate blood collection tubes per Sample #1 and Sample #2 requirements. Test results may be obtained from medical records or from testing performed during the study screening period
•Has been on a stable unchanged ART regimen consisting of two or more drugs from two or more antiretroviral drug classes for at least six consecutive months (defined as 180 consecutive days) prior to entry.
•Has no prior history of switching ART regimens for reasons related to treatment failure based on parent/guardian report and/or available medical records.
•Note: Participants undergoing dose modifications for growth or who have switched to a new formulation due to toxicity, tolerability, or changes in national treatment guidelines are considered eligible per this inclusion criterion. Treatment failure should be defined by local guidelines.
•From a specimen collected less than six months (defined as within 179 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:
•<50 copies/mL, or
•less than the lower limit of detection of the assay
•From a specimen collected in the 6-18 months (defined as 180 to 545 days) prior to entry, has at least one of the following documented plasma HIV-1 RNA results:
•<50 copies/mL, or
•less than the lower limit of detection of the assay
•At screening, a documented plasma HIV-1 RNA <50 copies/mL.
•Note: HIV-1 RNA test results at screening cannot be used to satisfy previously listed inclusion criterion. If participant does not have a documented HIV-1 RNA test result at screening that satisfies previously listed criteria, they should be referred for standard of care testing and return at a later date for screening.
•Has normal, Grade 1, or Grade 2 results for all the following laboratory tests at screening (i.e., within 28 days prior to entry) based on grading per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events:
•AST (<5.0 x ULN)
•ALT (<5.0 x ULN)
•Total bilirubin (<2.6 x ULN)
•Lipase (<3 x ULN)
•Estimated glomerular filtration rate (eGFR; ≥60 ml/min/1.73 m2)
•Platelets (≥50,000 cells/mm3 or ≥50.00 x 109 cells/L)
•Hemoglobin (≥8.5 g/dL or ≥5.25 mmol/L)
•Neutrophils (≥600 cells/mm3)
•Note: Laboratory tests may be repeated during the study screening period (i.e., within 28 days prior to entry), with the latest result used for eligibility determination. ALT and total bilirubin should also be assessed
•Has no evidence of chronic hepatitis B infection based on hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), and hepatitis B surface antibody (HBsAb) testing at screening; any of the following three combinations of test results are acceptable for inclusion:
•HBsAg negative, HBcAb negative, HBsAb negative
•HBsAg negative, HBcAb negative, HBsAb positive
•HBsAg negative, HBcAb positive, HBsAb positive
•At screening, has a mean QTc interval (based upon a triplicate reading) less than or equal to 450 msec based on an electrocardiogram (ECG) automated machine readout or calculated using the Fridericia formula.
•For female participants of childbearing potential, not pregnant based upon negative blood or urine pregnancy test at entry. Childbearing potential is defined as nine years of age or older and:
•Having reached menarche or
•Engaging in sexual activity (self-reported) that could lead to pregnancy
•For female participants of childbearing potential who are engaging in sexual activity (self-reported) that could lead to pregnancy, at entry, currently using at least one allowable highly effective method of contraception and agrees to use at least one allowable highly effective method of contraception throughout study participation and for at least 30 days after last oral product use and 48 weeks after last injectable study product use.
•Highly effective methods of contraception include:
•Surgical sterilization (i.e., hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy)
•Contraceptive intrauterine device or intrauterine system
•Subdermal contraceptive implant
•Progestogen injections
•Combined estrogen and progestogen oral contraceptive pills
•Percutaneous contraceptive patch
•Contraceptive vaginal ring
•Inclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase
•All participants enrolled in Cohort 1 or Cohort 2a will be assessed for eligibility to progress from the oral lead-in phase (Step 1) to the injection phase (Step 2), primarily based on the safety assessments from the Step 1 Week 4a study visit. Clinical assessments conducted prior to administering the first injection at the Week 4b visit will also be used to confirm eligibility to receive the injectable study product.
•All of the following criteria must be met in order for a participant enrolled in Cohort 1 or Cohort 2a to be included in Step 2
•Currently enrolled as a participant in Step
•Has normal, Grade 1, or Grade 2 results from all of the following laboratory test results based upon specimens collected at the Week 4a study visit or from confirmatory repeat testing of Week 4a study visit laboratory tests:
另有 16 项未显示

排除标准

•, Step 1: Entry for Cohort 1, Cohort 2a, and Cohort 2b
•Potential participants must be excluded from the study if any of the conditions specified below are identified during the screening period (i.e., within 28 days prior to study entry). The screening period begins when parental permission and informed assent (if applicable) are obtained and ends immediately prior to enrollment. For criteria involving a potential participant's medical history, it is expected that each exclusionary condition will be assessed at screening and subsequently reviewed and confirmed on the day of study entry, prior to enrollment. In these criteria, "at entry" is used to refer to the day of enrollment in the study
•Within 6 months prior to entry, any HIV-1 RNA value >400 copies/mL OR two consecutive "viral blips," defined as an HIV-1 RNA value ≥50 copies/mL but ≤400 copies/mL.
•As determined by the IoR or designee, and based on available medical records, known or suspected resistance to NNRTIs.
•Note: Prior receipt of NNRTIs for prophylaxis or treatment is not exclusionary
•As determined by the IoR or designee, and based on available medical records, known or suspected resistance to INSTIs.
•Ongoing congestive heart failure, symptomatic arrhythmia, or any current clinically significant cardiac disease, as determined by the IoR or designee, and based on available medical records.
•Has any of the following, as determined by the IoR or designee based on participant/parent/guardian report and available medical records:
•Current hepatitis C infection
•Current clinically significant hepatic disease
•Current or anticipated need for chronic anti-coagulation
•History of known or suspected bleeding disorder, including a history of prolonged bleeding
•History of sensitivity to heparin or heparin-induced thrombocytopenia, as determined by the IoR or designee, based on available medical records
•Risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, hypomagnesemia)
•Known or suspected allergy to study product components.
•Known phobia to needles
•More than one seizure within one year (defined as within 365 days) prior to entry, or unstable or poorly controlled seizure disorder, as determined by the IoR or designee, and based on available medical records.
•Has the following combination of laboratory test results at screening (i.e., from specimens collected within 28 days prior to entry): ALT greater than or equal to 3 x ULN and total bilirubin greater than or equal to 1.5 x ULN and direct bilirubin greater than 35% of total bilirubin.
•At entry, known active tuberculosis infection, as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
•At entry, any ongoing pancreatitis as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
•At entry, has symptoms suggestive of active coronavirus disease 2019 (COVID-19) or test results or contacts that require quarantine per local clinical practice, public health, and/or infection control guidelines as determined by the IoR or designee based on participant/parent/guardian report and available medical records.
•Note: Potential participants with symptoms suggestive of active COVID-19, test results, and/or contacts that require quarantine may resume screening (or be re-screened) after symptoms have resolved and applicable quarantine requirements have been completed.
•Receipt of any prohibited medication within 7 days prior to entry, with the exception of antiviral agents that are part of the participant's ART regimen, as determined by the site investigator based on participant/parent/guardian report and available medical records
•Note: Medications and vaccines approved for emergency use (e.g., COVID vaccines) that do not appear in the IMPAACT 2036 Prohibited and Precautionary Medications listing are not exclusionary may be administered as per standard of care.
•Any past or current exposure to CAB LA or RPV LA
•At entry, based on physical examination, has a current inflammatory skin condition that compromises the safety of intramuscular injections, as determined by the IoR or designee.
•At entry, based on physical examination, has a dermatological condition overlying the buttock or upper thigh region, which, in the IoR or designee's opinion, may interfere with the interpretation of injection site reactions.
•Enrolled in another clinical trial of an investigational agent, device, or vaccine.
•Has any documented or suspected clinically significant medical or psychiatric condition or any other condition or social circumstance that, in the opinion of the site investigator, would make participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
•Exclusion Criteria, Step 2: Continuation for Cohort 1 and Cohort 2a to injection phase
•Participants in Cohort 1 or Cohort 2a who meet any of the following criteria will be excluded from Step 2:
•Has permanently discontinued oral study product.
•Occurrence of any grade 3 or higher adverse event assessed as related to study product during Step
•Any other condition or social circumstance situation that, in the opinion of the IoR or designee, would make continued study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
•Exclusion Criteria for Parents/Caregivers
•Any condition or social circumstance situation that, in the opinion of the IoR or designee, would make study participation unsafe for the caregiver or the child study participant, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

研究组 & 干预措施

Cohort 2A

Experimental

Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.

干预措施: Long acting CAB injectable + long acting RPV injectable (Drug)

Cohort 2B

Experimental

Cohort 2B: Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.

干预措施: Long acting CAB injectable + long acting RPV injectable (Drug)

Cohort 1

Experimental

Cohort 1 will receive Once daily oral CAB + oral RPV through the Week 4b visit, followed by intramuscular injection doses of CAB LA + RPV LA every four weeks (Q4W dosing regimen) or every eight weeks (Q8W dosing regimen)

干预措施: Once daily CAB tablet + RPV tablet (Drug)

Cohort 1

Experimental

干预措施: Long acting CAB injectable + long acting RPV injectable (Drug)

Cohort 2A

Experimental

Cohort 2A: Once daily doses of oral CAB + oral RPV through the Week 4b visit, followed by Q4W or Q8W intramuscular injection doses of CAB LA + RPV LA.

干预措施: Once daily CAB tablet + RPV tablet (Drug)

结局指标

主要结局

AUC (Cohort 1, tablets)

时间窗: At week 2

Area under the curve from start of dose to 8 hours post dose

CL/F (Cohort 1, tablets)

时间窗: At week 2

apparent clearance from start of dose to 8 hours post dose

Cmax (Cohort 1, tablets)

时间窗: At week 2

Peak concentration from start of dose to 8 hours post dose

Tmax (Cohort 1, tablets)

时间窗: At week 2

Time of maximal concentration from start of dose to 8 hours post dose

Week 5 concentrations (C5WK) (Cohort 1, injections)

时间窗: Through week5

Week 12 concentrations (C12WK) (Cohort 1, injections)

时间窗: Through week 12

Proportion of children who experience a drug related safety event during the CAB + RPV oral lead-in period (Cohort 1)

时间窗: Through week 4a

Proportion of children who experience a grade 3 of higher adverse event during the CAB + RPV oral lead-in period (Cohort 1)

时间窗: Through week 4a

Proportion of children who experience an SAE during the CAB + RPV oral lead-in period (Cohort 1)

时间窗: Through week 4a

Proportion of children who experience a drug-related safety failure event during the 24 weeks of CAB + RPV (oral and injectable) (Cohort 1)

时间窗: Week 4b through week 28

Pre-dose concentrations (C0) (Cohort 1, tablets)

时间窗: At week 2

Accumulation Ratio at week 24 and week 8 (Cohort 1, injections)

时间窗: At week 8 and 24

Trough concentrations (Ct) prior to IM doses through Week 24 (Cohort 1, injections)

时间窗: Through week 24

Proportion of children who experience premature permanent discontinuation study treatment due to an adverse event during the 24 weeks of CAB + RPV (oral and injectable) (Cohort 1)

时间窗: Week 4b through week 28

Proportion of children who experience premature permanent discontinuation study treatment due to an adverse event during the CAB + RPV oral lead-in period (Cohort 1)

时间窗: Through week 4a

Proportion of children who experience a grade 3 or higher adverse event during the 24 weeks of CAB + RPV (oral and injectable) (Cohort 1)

时间窗: Week 4b through week 28

Proportion of children who experience an SAE during the 24 weeks of CAB + RPV (oral and injectable) (Cohort 1)

时间窗: Week 4b through week 28

次要结局

Accumulation ratios Wk 24:Wk 8 and Wk 48: Wk 8 (Cohort 2a), Wk 20:Wk4 and Wk 44: Wk 4 (Cohort 2b(At week 8, 48 and 72)
Ct prior to IM doses through Week. 24 and Week. 48 (Cohort 2a)(At Week. 24 and Week. 48)
Ct prior to IM doses through Wk. 20 and Wk. 44 (Cohort 2b)(At week 20 and 44)
Proportion of children who experience a drug-related safety failure event through Weeks 48 and 72 of CAB + RPV (oral and injectable) (Cohort 1)(Through week 48 and 72)
Proportion of children who experience a grade 3 or higher adverse event through Weeks 48 and 72 of CAB + RPV (oral and injectable) (Cohort 1)(Through week 48 and 72)
Proportion of children who experience an SAE through Weeks 48 and 72 of CAB + RPV (oral and injectable) (Cohort 1)(Through week 48 and 72)
Proportion of children who experience premature permanent discontinuation study treatment due to an adverse event through Weeks 48 and 72 of CAB + RPV (oral and injectable) (Cohort 1)(Through week 48 and 72)
Proportion of children who have HIV-1 RNA <50 and ≥50, copies/ml at Weeks 24, 48, and 72 using the FDA Snapshot algorithm (Cohort 1)(At weeks 24, 48 and 72)
Proportion of children who have HIV-1 RNA <200 and ≥200 copies/ml at Weeks 24, 48, and 72 using the FDA Snapshot algorithm (Cohort 1)(At weeks 24, 48 and 72)
Proportion of children with confirmed virologic failure at Weeks 24, 48 and 72 while on CAB + RPV (Cohort 1)(At weeks 24, 48 and 72)
Child and/or parent/caregiver responses to questionnaires about CAB or RPV side effects, pain associated with injections, and injection site reactions at Weeks 24, 48, and 72 (Cohort 1)(At Weeks 24, 48, and 72)
Child and/or parent/caregiver reported attitudes about CAB or RPV, including willingness to use at Weeks 24, 48, and 72 (Cohort 1)(At weeks 24, 48 and 72)
Proportion of participants who had genotypic and phenotypic resistance to CAB or RPV among children who experience virologic failure while on CAB + RPV (Cohort 1)(Through week 72)
Median for CD4 count and percentage at Weeks 24, 48 and 72 (Cohort 1)(At weeks 24, 48 and 72)
Median change from baseline CD4 count and percentage at Weeks 24, 48 and 72 (Cohort 1)(At weeks 24, 48 and 72)
Child and/or parent/caregiver response to questionnaires (Cohort 2)(at week 44 and 48)
Child and/or parent/caregiver reported attitudes about CAB (Cohort 2) or RPV, including willingness to use for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable)(At week 44 and 48)
Proportion of children who experience a drug-related safety failure event during the 48 weeks of CAB + RPV (oral and injectable) OR the 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of children who experience a grade 3 or higher adverse event during the 48 weeks of CAB + RPV (oral and injectable) OR the 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of children who experience an SAE during the 48 weeks of CAB + RPV (oral and injectable) OR the 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of children who experience premature permanent discontinuation study treatment due to an adverse event during the 48 weeks of CAB + RPV (oral and injectable) OR the 44 weeks of CAB LA + RPV (Cohort 2) LA (injectable)(At week 44 and 48)
Proportion of children who have HIV-1 RNA <50 and ≥50, copies/ml using the FDA Snapshot algorithm for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of children who have HIV-1 RNA <200 and ≥200 copies/ml using the FDA Snapshot algorithm for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of children with confirmed virologic failure while on treatment for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Median and Interquartile Range for CD4 count and percentage for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Median and Interquartile Range change from baseline CD4 count and percentage for children who are on 48 weeks of CAB + RPV (oral and injectable) OR 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
Proportion of participants who had genotypic and phenotypic resistance to CAB and RPV among children who experience virologic failure while on 48 weeks of CAB + RPV (oral and injectable) OR while on 44 weeks of CAB LA + RPV LA (injectable) (Cohort 2)(At week 44 and 48)
LA dosing: Ct prior to IM doses at Wk. 48 and Wk. 72 and accumulation ratios (Wk. 48:Wk. 8 and Wk. 72:Wk. 8) (Cohort 1)(At week 8 and 48)

研究者

发起方

National Institute of Allergy and Infectious Diseases (NIAID)

申办方类型

Nih

责任方

Sponsor

研究点 (24)

Loading locations...

相似试验

已完成

1 期

Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant TuberculosisRifampicin Resistant TuberculosisTuberculosis

NCT05586230National Institute of Allergy and Infectious Diseases (NIAID)32

终止

1 期

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic Leukemia

NCT05038800Merck Sharp & Dohme LLC13

已完成

1 期

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy SubjectsHealthy VolunteersPharmacokinetics of ASP7962

NCT02136316Astellas Pharma Europe B.V.48

已完成

1 期

Study to Assess PK, Safety and Tolerability in Healthy SubjectsAcute Ischemic Stroke

NCT06380699Changzhou Qianhong Bio-pharma Co., Ltd.56

已完成

1 期

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

NCT01916993Neurocrine Biosciences24